Chondral DefectKNAMICNCT03625180
An Observational, Prospective Study of Patients With Chondral and/or Osteochondral Defects of the Knee Treated With NAMIC
An observational study of Chondral Defect and Osteochondral Defect, run by Jordi Villalba Modol at 1 site in Spain.
Trial summary
It is a prospective observational study of hospital cases. The objective is to determine the decrease of lesion size and the regeneration of chondral tissue in femoral condyle cartilage defect treated with NAMIC. 24 patients will be included Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chondral Defect, Osteochondral Defect
- What is being tested?
- NAMIC: nanofractured autologous matrix-induced chondrogenesis
- How many people
- 24 participants
- Where
- 1 siteSpain
- Study dates
- 18 Jul 2018to Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with Outerbridge grade III or IV cartilage lesions localized in the medial or lateral condyle of the knee.
Who may be able to join
- Patients with Outerbridge grade III or IV cartilage lesions localized in the medial or lateral condyle of the knee (Chondral lesions were diagnosed by magnetic resonance T2 mapping and graded according to the Outerbridge classification.).
- Size of lesion between 1.5 cm2 and 6 cm2 (specify size, alignment, and telemetry)
- Body mass index ≤ 30 kg/m2.
- Age 18 to 50.
- Stable or stabilized knee, with normal axis (<+/-5º)
- The patients included in the study will accept to follow the recommended physiotherapy programme, including exercises to be performed at home.
Who cannot join
- Any disease that, in the opinion of the investigator, may prevent the patient from completing the study or interfere with the assessment of the efficacy or security of the treatment proposed.
- Patients with any disorder of coagulation of the blood or receiving anticoagulant therapy.
- Patients with rheumatoid arthritis, bi- or tri-compartmental arthritis such as chondrocalcinosis and gout.
- Malalignment of affected leg with valgus or varus > 5º (and/or > vs. contralateral leg)
- Chondral lesion of the tibial plateau (mirror lesions).
- Known allergy to metal (nitinol or stainless steel) and/or pork products.
- Any general pathology that may not allow long-term data collection.
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Corporació Sanitària Parc Taulí
Sabadell, Barcelona, 08208
Jordi Villalba-Modol, MD, +34937231010, jvillalba@tauli.cat
Jordi Villalba-Modol, MD
About this study
Official title: An Observational, Prospective, Multicentre Study of Patients With Outerbridge Grade III / IV Chondral and/or Osteochondral Defects of the Knee Treated With Nanofractured Autologous Matrix-induced Chondrogenesis
It is a prospective observational study of hospital cases. The objective is to determine the decrease of lesion size and the regeneration of chondral tissue in femoral condyle cartilage defect treated with NAMIC.
24 patients will be included
Read the detailed description
Background: The treatment of chondral lesions remains a challenge for orthopaedic surgeons. They are most common in young active individuals and result in substantial impairment of quality of life. The conventional joint treatment methods available to date, such as Pridie-type perforations, microfractures using open or arthroscopic approaches and mosaicoplasty are far from satisfactory. Cell-based therapies have also been tested in more advanced research centres.
Nanofractured autologous matrix-induced chondrogenesis (NAMIC) is a simple, easily reproducible implantation technique that can be performed in most hospitals to improve clinical outcomes of patients with severe chondral lesions.
The present observational, multicentre study is based on the recently published NAMIC© technique (Behrens_Bentin_06_2015 The Knee) that reports significant improvements over previous techniques, especially regarding the reduction of rehabilitation period. Our main aim is to confirm these results in a larger sample.
NAMIC is a matrix-guided minimally invasive stimulation of the subchondral bone marrow.
The present study will collect data on the usual medical practice when the NAMIC technique is used to treat grade III or IV symptomatic focal cartilage lesions.
According to Chen 2011 JOR 2011, nanofracture achieves a uniform blood drainage and pluripotential cell recruitment of the bone marrow through the depth of the 9mm perforations. As observed by Eldracher AJS 2014, it also allows a faster recovery thanks to the minimal aggression on the subchondral bone as the diameter of the drill holes is 1 mm.
According to the study published by Benthien JP, in Knee Surg Sports Traumatol Arthrosc 2011 Aug:19(8):1316-9, AMIC induces satisfactory chondrogenesis.
To date, the combination of nanofracture plus Cartimaix membrane has not been used in patients in our environment.
Hypothesis: The NAMIC technique is useful for the treatment of chondral lesions of the knee.
Objectives:
Main: Determine the decrease of lesion size and the regeneration of chondral tissue in femoral condyle cartilage defect treated with NAMIC.
Secondary: Assess the clinical results regarding pain, articular rigidity and function before surgery and 12 months postoperatively.
Description of technique: After localization of the chondral lesion, the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
Nanofracture is a subchondral bone perforation procedure using a 1mm-thick needle, with a depth of 9mm, 2mm apart , in a systemic spiral fashion in the whole periphery of the lesion, using a specially-designed kit (Nano FX, Arthrosurface, USA). It allows a reproducible, effective and minimally invasive stimulation of the subchondral bone. Nanofracture achieves a uniform blood drainage and pluripotential cell recruitment of the bone marrow through the depth of the 9mm perforations.
Subsequently, the lesion is traced with a template included in the kit (Cartimaix, Matricel, Germany), and the membrane is cut to the adequate size, bearing in mind that it expands 10% with hydration. The two-layer membrane is then implanted on the lesion, and left to be hydrated by the blood from the stimulated area (Image 2). Cartimaix is a two-sided type I/ III collagen and elastine membrane that includes a smooth side (intraarticular) and a rough side facing the cartilage. Finally, fibrin sealing is achieved (Tissel, Baxter, USA). This technique can be combined with a graft in osteochondral injuries, but these are not contemplated in the present study.
Variables:
Main variable: Amount of tissue repaired, calculating the filling area of the lesion. Magnetic resonance will be used to determine the filling area at 12-month outpatient follow-up visit.
The following information will be collected: a) size and localisation of the lesion; b) alignment determined by telemetry; c) surgeries of cartilage or that may directly or indirectly affect cartilage such as meniscectomy, osteotomy, microfracture, mosaicoplasty or ligament repair.
A series of intraoperative pictures will be collected.
Secondary variables:
Pain: Visual analogue scale (VAS) Function and articular rigidity: KOOS scale, Tegner Activity Scale during routine outpatients visits, at preoperative visit and at 12 months.
- Conditions
- Chondral Defect, Osteochondral Defect
- Being tested
- NAMIC: nanofractured autologous matrix-induced chondrogenesis
- Keywords
- nanofractured autologous matrix-induced chondrogenesis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NAMIC: nanofractured autologous matrix-induced chondrogenesisBiological
the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
| Study group | Role | What they receive |
|---|---|---|
| Treatment | NAMIC technique Receives: Biological: NAMIC: nanofractured autologous matrix-induced chondrogenesis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amount of tissue repaired
Amount of tissue repaired, calculating the filling area of the lesion. Magnetic resonance will be used to determine the filling area at 12-month outpatient follow-up visit.
Measured: 12 months
Secondary outcomes (7)
Localisation of the lesion
THe localisation of the lesion will be described, using magnetic resonance.
Measured: preoperative, and at 12 months
Size of the lesion
Magnetic resonance will be used to determine the size of the lesion, measured in mm.
Measured: preoperative, and at 12 months
Mechanical alignment
Limb alignment (anatomic relation of bone axes) determined by telemetry. Measured in degrees.
Measured: preoperative, and at 12 months
Surgeries of cartilage or that may directly or indirectly affect cartilage
Surgeries of cartilage or that may directly or indirectly affect cartilage such as meniscectomy, osteotomy, microfracture, mosaicoplasty or ligament repair
Measured: 12 months
Pain in the knee: Visual Analogue Scale
Pain measured with a Visual Analogue Scale (VAS), which is a self-reported, single question, 11 point scale (from 0 no pain, to 10 unbearable pain).
Measured: preoperative, and at 12 months
KOOS score
KOOS (Knee injury and Osteoarthritis Outcome Score) is a self-reported measure including 5 subscales: Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL). Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. KOOS subscale scores will be aggregated and averaged as the primary outcome.
Measured: preoperative, and at 12 months
Activity level: Tegner Activity Scale
Patient's activity level measured with the Tegner Activity Scale (TAS). It is a self-reported measure including 11 levels of activity (from 0 to 10) measuring work and sport activities graded numerically.
Measured: preoperative, and at 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2018
- Study start18 Jul 2018
- Primary completionDec 2020 (estimated)
- Study completionDec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chondral DefectStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jordi Villalba Modol
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jordi Villalba Modol, Corporacion Parc Tauli
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03625180
- Sponsor's protocol ID
- 2017584
- Acronym
- KNAMIC
- Status last verified
- Aug 2018
- First submitted
- 10 Jul 2018
- Last updated
- 10 Aug 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational, Prospective, Multicentre Study of Patients With Outerbridge Grade III / IV Chondral and/or Osteochondral Defects of the Knee Treated With Nanofractured Autologous Matrix-induced Chondrogenesis
- ClinicalTrials.gov ID
- NCT03625180
- Acronym / sponsor ID
- KNAMIC / 2017584
- Conditions
- Chondral Defect, Osteochondral Defect
- Keywords
- nanofractured autologous matrix-induced chondrogenesis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Jordi Villalba ModolUniversity, hospital or other
- Study start
- 18 Jul 2018 (actual)
- Primary completion
- Dec 2020 (estimated)
- Study completion
- Dec 2020 (estimated)
- First posted
- 10 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is a prospective observational study of hospital cases. The objective is to determine the decrease of lesion size and the regeneration of chondral tissue in femoral condyle cartilage defect treated with NAMIC.
24 patients will be included
Detailed description
Background: The treatment of chondral lesions remains a challenge for orthopaedic surgeons. They are most common in young active individuals and result in substantial impairment of quality of life. The conventional joint treatment methods available to date, such as Pridie-type perforations, microfractures using open or arthroscopic approaches and mosaicoplasty are far from satisfactory. Cell-based therapies have also been tested in more advanced research centres.
Nanofractured autologous matrix-induced chondrogenesis (NAMIC) is a simple, easily reproducible implantation technique that can be performed in most hospitals to improve clinical outcomes of patients with severe chondral lesions.
The present observational, multicentre study is based on the recently published NAMIC© technique (Behrens_Bentin_06_2015 The Knee) that reports significant improvements over previous techniques, especially regarding the reduction of rehabilitation period. Our main aim is to confirm these results in a larger sample.
NAMIC is a matrix-guided minimally invasive stimulation of the subchondral bone marrow.
The present study will collect data on the usual medical practice when the NAMIC technique is used to treat grade III or IV symptomatic focal cartilage lesions.
According to Chen 2011 JOR 2011, nanofracture achieves a uniform blood drainage and pluripotential cell recruitment of the bone marrow through the depth of the 9mm perforations. As observed by Eldracher AJS 2014, it also allows a faster recovery thanks to the minimal aggression on the subchondral bone as the diameter of the drill holes is 1 mm.
According to the study published by Benthien JP, in Knee Surg Sports Traumatol Arthrosc 2011 Aug:19(8):1316-9, AMIC induces satisfactory chondrogenesis.
To date, the combination of nanofracture plus Cartimaix membrane has not been used in patients in our environment.
Hypothesis: The NAMIC technique is useful for the treatment of chondral lesions of the knee.
Objectives:
Main: Determine the decrease of lesion size and the regeneration of chondral tissue in femoral condyle cartilage defect treated with NAMIC.
Secondary: Assess the clinical results regarding pain, articular rigidity and function before surgery and 12 months postoperatively.
Description of technique: After localization of the chondral lesion, the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
Nanofracture is a subchondral bone perforation procedure using a 1mm-thick needle, with a depth of 9mm, 2mm apart , in a systemic spiral fashion in the whole periphery of the lesion, using a specially-designed kit (Nano FX, Arthrosurface, USA). It allows a reproducible, effective and minimally invasive stimulation of the subchondral bone. Nanofracture achieves a uniform blood drainage and pluripotential cell recruitment of the bone marrow through the depth of the 9mm perforations.
Subsequently, the lesion is traced with a template included in the kit (Cartimaix, Matricel, Germany), and the membrane is cut to the adequate size, bearing in mind that it expands 10% with hydration. The two-layer membrane is then implanted on the lesion, and left to be hydrated by the blood from the stimulated area (Image 2). Cartimaix is a two-sided type I/ III collagen and elastine membrane that includes a smooth side (intraarticular) and a rough side facing the cartilage. Finally, fibrin sealing is achieved (Tissel, Baxter, USA). This technique can be combined with a graft in osteochondral injuries, but these are not contemplated in the present study.
Variables:
Main variable: Amount of tissue repaired, calculating the filling area of the lesion. Magnetic resonance will be used to determine the filling area at 12-month outpatient follow-up visit.
The following information will be collected: a) size and localisation of the lesion; b) alignment determined by telemetry; c) surgeries of cartilage or that may directly or indirectly affect cartilage such as meniscectomy, osteotomy, microfracture, mosaicoplasty or ligament repair.
A series of intraoperative pictures will be collected.
Secondary variables:
Pain: Visual analogue scale (VAS) Function and articular rigidity: KOOS scale, Tegner Activity Scale during routine outpatients visits, at preoperative visit and at 12 months.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment | – | Biological: NAMIC: nanofractured autologous matrix-induced chondrogenesisNAMIC technique |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with Outerbridge grade III or IV cartilage lesions localized in the medial or lateral condyle of the knee.
Key inclusion criteria (6 listed)
- Patients with Outerbridge grade III or IV cartilage lesions localized in the medial or lateral condyle of the knee (Chondral lesions were diagnosed by magnetic resonance T2 mapping and graded according to the Outerbridge classification.).
- Size of lesion between 1.5 cm2 and 6 cm2 (specify size, alignment, and telemetry)
- Body mass index ≤ 30 kg/m2.
- Age 18 to 50.
- Stable or stabilized knee, with normal axis (<+/-5º)
Key exclusion criteria (7 listed)
- Any disease that, in the opinion of the investigator, may prevent the patient from completing the study or interfere with the assessment of the efficacy or security of the treatment proposed.
- Patients with any disorder of coagulation of the blood or receiving anticoagulant therapy.
- Patients with rheumatoid arthritis, bi- or tri-compartmental arthritis such as chondrocalcinosis and gout.
- Malalignment of affected leg with valgus or varus > 5º (and/or > vs. contralateral leg)
- Chondral lesion of the tibial plateau (mirror lesions).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NAMIC: nanofractured autologous matrix-induced chondrogenesisthe NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany). | Biological | Treatment |
Primary outcome
Amount of tissue repaired
Time frame: 12 months
Amount of tissue repaired, calculating the filling area of the lesion. Magnetic resonance will be used to determine the filling area at 12-month outpatient follow-up visit.
7 secondary outcomes
Localisation of the lesion
Time frame: preoperative, and at 12 months
Size of the lesion
Time frame: preoperative, and at 12 months
Mechanical alignment
Time frame: preoperative, and at 12 months
Surgeries of cartilage or that may directly or indirectly affect cartilage
Time frame: 12 months
Pain in the knee: Visual Analogue Scale
Time frame: preoperative, and at 12 months
KOOS score
Time frame: preoperative, and at 12 months
Activity level: Tegner Activity Scale
Time frame: preoperative, and at 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2018.
- Individual participant dataSharing planned: Undecided
Related trials for Chondral Defect
RecruitingPhase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Chondral Defect, Articular Cartilage Defect
RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Chondral Defect, Osteochondritis Dissecans (OCD)
Not yet recruiting
Biologic Augmentation of Osteochondral Allograft Transplantation in the Knee
Osteochondral Defect, Articular Cartilage Defect
RecruitingPhase 1
AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip
Hip Arthroscopy, Articular Cartilage Defect
Recruiting
Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy
Chondral Lesion of the Knee, Meniscal Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chondral Defect and Osteochondral Defect, run by Jordi Villalba Modol at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amount of tissue repaired (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2018.